Back in March, drug giant Novartis donated 130 million doses of the anti-malaria drug hydroxychloroquine to the global Wuhan coronavirus (COVID-19) pandemic response. But the U.S. Food and Drug Administration (FDA) has been directly interfering with its distribution, which has prompted a new lawsuit.
The American Association of Surgeons and Physicians (AASP) has filed a complaint for declaratory and injunctive relief against the Department of Health & Human Services (HHS), along with the FDA and the Biomedical Advanced Research & Development Authority, two of its constituent agencies. Also named in the suit are the “lead officers” of these agencies.
According to the AASP, the FDA has been engaged in “irrational interference” concerning patients having “timely access” to hydroxychloroquine. Despite the fact that large amounts of hydroxychloroquine were donated to the federal government for “prompt distribution,” the FDA has seen to it that very few of these drug doses make it out to patients.
On March 28, just days after Novartis donated large quantities of hydroxychloroquine to the federal government, the FDA issued an “Emergency Use Authorization” that essentially prohibited the drug from being administered except in the case of “already-hospitalized patients for whom clinical trials are unavailable.”
“Through a biased, unlawful process described in greater detail below,” the suit states, “FDA officials from prior administrations acted contrary to the wishes of President Donald Trump, by arbitrarily limiting use of HCQ from the Strategic National Stockpile (SNS) to prescribe to adolescent and adult patients hospitalized with COVID-19, as appropriate, when a clinical trial is not available or feasible.”
AASP lawsuit specifically names Barack Obama appointees as complicit in withholding hydroxychloroquine from coronavirus patients
Though the FDA approved hydroxychloroquine as safe for human use some 65 years ago, partisan politics has clearly gotten in the way of its use now. Holdovers from previous administrations, including Barack Obama’s, have been fighting against the widespread distribution of this drug, even though it was given to the government for this specific purpose.
Rick Bright, “a Barack Obama-appointed official who is outspokenly critical of President Trump,” according to the lawsuit, has “personally opposed making HCQ widely available to the public from the federal SNS.” The lawsuit adds that Bright has further “distorted the agency process to arbitrarily and unjustifiably limit access by patients to HCQ received as donations by the federal government for the purpose of making it available promptly to the public.”
HCQ, it turns out, “is safer than numerous medications that are widely available over the counter” with no prescription. These OTC drugs that are more dangerous include the common painkiller acetaminophen (Tylenol), as well as sleeping pills like diphenhydramine.
Hydroxychloroquine is also likely safer than the experimental remdesivir drug that the deep state is pushing instead of hydroxychloroquine for treating the Wuhan coronavirus (COVID-19). As it turns out, remdesivir fetches a much higher price per dose than generic hydroxychloroquine, which explains why Bright, Anthony Fauci, and other swamp holdovers have been pushing it so aggressively over hydroxychloroquine.
This interference with the distribution of hydroxychloroquine also affects the political process “by which the United States selects its president: national political conventions,” the lawsuit goes on to contend.
“For nearly two centuries, thousands of delegates attend a national political convention together to nominate their candidate for president and to present their slate to the American public. Continued, irrational interference by Defendants with a safe prophylaxis for COVID-19 has the effect of infringing on the right of the people to hold national political conventions, which have been an essential part of our presidential elections since at least 1832.”
You can read the full lawsuit at this link.
Source for Story: